Imiquimod cream (Aldara) for superficial basal cell carcinoma: NPS - Better choices, Be... - 0 views
Aldara - About sBCC - 0 views
Imiquimod. DermNet NZ - 0 views
Imiquimod - Wikipedia - 0 views
Mohs' Surgery ~ Animation - 0 views
21152128[PMID] - PMC result - 0 views
Management of superficial basal cell carcinoma: focus on imiquimod - 0 views
-
There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides outcomes only marginally less satisfactory than surgery. There would be a place for imiquimod in treating patients with frequent multiple primary lesions when access to surgery is difficult or where clinical judgment may be influenced by patient factors as reported in some of the studies, eg, where patients may have contraindications to surgery. It was noted that if recurrences occurred in this study they mostly occurred during the first 9 months after the end of treatment. The initial response was therefore predictive of long-term outcome so these authors recommend and encourage continued monitoring of skin lesions.
Management of superficial basal cell carcinoma: fo... [Clin Cosmet Investig Dermatol. 2... - 0 views
-
To date one long-term study indicates a treatment success rate of 78%-81% and that initial response is a predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. Future research will compare this preparation to the gold standard treatment for superficial BCC - surgical excision.
Imiquimod 5% cream for the treatment of superficia... [J Am Acad Dermatol. 2004] - PubM... - 0 views
-
Composite clearance rates (combined clinical and histological assessments) for the 5 and 7x/week imiquimod groups were 75% and 73%, respectively. Histological clearance rates for the 5 and 7x/week imiquimod groups were 82% and 79%, respectively. Increasing severity of erythema, erosion, and scabbing/crusting was associated with higher clearance rates. CONCLUSION: Imiquimod appears to be safe and effective for the treatment of sBCC when compared with vehicle cream. The difference in clearance rates between the two imiquimod dosing groups was not significant. The 5x/week regimen is recommended.